

Neuronascent to Present at Life Sciences Summit 2009

Clarksville, MD, September 15, 2009 – **Neuronascent, Inc.**, a privately-held biotechnology company developing novel, neurogenic small-molecule drugs for the treatment of depression, Alzheimer's, Parkinson's and other neurodegenerative diseases, today announced that Dr. Judith Kelleher-Andersson, President and Chief Scientific Officer, will present at the Life Sciences Summit 2009 – *Showcasing Innovation, Promoting Collaboration*. The Summit brings the world's leading companies together with the world's most innovative scientists to explore the next generation of biomedical solutions, the proceeds from which will help seed a bio-innovation research fund to support the discovery, development, translation, and commercialization of these new technologies. The event will take place on September 23-24, 2009 at Hyatt Regency Long Island in Hauppauge, New York.

“We are proud to have been selected to showcase the potential of our first-in-class CNS drug candidates and our neurogenesis platform,” said Dr. Kelleher-Andersson. “Our participation in the Summit, with the nation's leading research institutions and top bioscience companies, supports our strategy for collaboration and innovation combining the best of business and the best of science.”

About Neuronascent, Inc.:

Founded in 2004 by Dr. Judith Kelleher-Andersson, Neuronascent, discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression and neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The Company is headquartered in Clarksville, MD and has facilities in Rockville and Walkersville, MD. For additional information, please visit www.neuronascent.com.

About The Center for Biotechnology, A New York State Center for Advanced Technology in Medical Biotechnology:

The Center for Biotechnology is a cooperative research and development partnership between universities, private industry and New York State. Located on the campus of Stony Brook University, the Center's technology development initiative has contributed to an active pipeline of more than forty commercially promising technologies, the commercialization of more than a dozen novel biomedical products, and the formation of eighteen new bioscience companies. The Center is funded by the New York Office of Science, Technology and Academic Research (NYSTAR). Visit www.biotech.sunysb.edu for more information on the Center.

Contact: Kathleen L. Mattis, CFO - kmattis@neuronascent.com